JF
Jim Faulkner
Non Executive Board Member at Vitarka Therapeutics
JF
Jim Faulkner
Non Executive Board Member at Vitarka Therapeutics
London, England
Overview
Jim Faulkner is an Independent Consultant specializing in Cell and Gene Therapy development and serves as a Non-Executive Director. With a background including roles at GlaxoSmithKline as VP in various departments and as SVP at Autolus Ltd., Faulkner's career highlights include leadership positions in biopharmaceutical development and significant contributions to the advancement of cell and gene therapy technologies.
Currently based in London, England, Jim Faulkner's expertise spans across the pharmaceutical industry, with notable roles at organizations such as GlaxoSmithKline, Autolus Ltd., and Cell and Gene Therapy Catapult, showcasing a strong focus on drug development, regulatory affairs, and clinical research within the biotechnology sector.
Work Experience
Independent Consultant
2023 - Current
Non Executive Board Member
2024
Non Executive Board Member
2024
Chief Technical Advisor
2024 - 2024
Chief Technology Officer
2020 - 2024
Ascidian Therapeutics is a biotechnology company that focuses on medical and clinical gene therapy.
Raised $90,000,000.00 from Apple Tree Partners and Apple Tree Partners.
Venture Partner
2020 - 2023
Apple Tree Partners is a venture capital firm that invests in pharmaceuticals, biotech, medtech, and healthcare services.
Raised $5,000,000.00.
SVP, Product Delivery
2015 - 2019
VP, CMC and Supply, Rare Disease Unit
2010 - 2015
Vice President, Biopharm Process Research
2007 - 2010
VP, Early Stage Biopharm Development
2004 - 2007
WW Director, Biopharm Analytical Sciences
2001 - 2004
Section Head, Molecular Analysis
1998 - 2000
Team Leader, Biopharmaceutical Analysis
1993 - 1998
Senior Clinical Scientist, Molecular Genetics
1987 - 1993
Research Assistant, Molecular Genetics
1986 - 1987